Furthermore, they recommend non-steroidal mineralocorticoid receptor antagonists (finerenone) in T2DM kidney disease patients with an eGFR ≥ 25 mL/min/1.73 m2, normal serum potassium, and albuminuria (ACR ≥30 mg/g), despite maximum tolerated doses of ARBs or ACE inhibitors, to reduce proinflammatory and profibrotic mediators [287,288]. This evidence concerns the gene ACE and kidney disorder.